Skip to main content
. 2022 Aug 10;9(6):3836–3845. doi: 10.1002/ehf2.14055

Table 2.

Medication history, administration during index hospitalization, and adherence at 1 year among NORIN‐STEMI participants by left ventricular ejection fraction at presentation

LVEF ≥50% (N = 468, 13%) LVEF 40–49% (N = 1482, 41%) LVEF 30–39% (N = 1357, 38%) LVEF <30% (N = 290, 8%)
Historical medications
Aspirin 46 (10%) 127 (9%) 156 (12%) 42 (15%)
Statin 45 (10%) 126 (9%) 153 (11%) 44 (15%)
Beta‐blocker 48 (10%) 159 (11%) 193 (14%) 51 (18%)
ACE inhibitor/ARB 45 (10%) 147 (9%) 188 (14%) 54 (19%)
Aldosterone receptor antagonist 1 (<1%) 9 (1%) 5 (<1%) 3 (1%)
Medications on arrival
Aspirin 466 (>99%) 1476 (>99%) 1353 (>99%) 288 (99.3%)
Statin 466 (>99%) 1476 (>99%) 1352 (>99%) 287 (99%)
P2Y12 inhibitor 468 (100%) 1474 (>99%) 1352 (>99%) 288 (99%)
Beta‐blocker 115 (25%) 294 (20%) 235 (17%) 25 (9%)
Anticoagulant 305 (65%) 1038 (70%) 914 (67%) 110 (38%)
Discharge medications, n (%) 1
Aspirin 455 (100%) 1432 (>99%) 1275 (>99%) 221 (100%)
Statin 453 (>99%) 1429 (>99%) 1266 (99%) 221 (100%)
P2Y12 inhibitor 452 (99%) 1426 (>99%) 1273 (>99%) 217 (98%)
Beta‐blocker 444 (98%) 1417 (99%) 1252 (98%) 216 (98%)
ACE inhibitor/ARB 363 (80%) 1164 (81%) 1250 (98%) 215 (97%)
Aldosterone receptor antagonist 97 (21%) 359 (25%) 883 (69%) 146 (68%)
Guideline‐directed medical therapies at 1 year (missing = 310, 10%), n (%) 2
Aspirin 334 (85%) 1076 (87%) 917 (85%) 156 (87%)
P2Y12 inhibitor 282 (72%) 805 (65%) 774 (72%) 118 (66%)
Statin 308 (79%) 991 (80%) 868 (80%) 149 (83%)
Beta‐blocker 309 (79%) 989 (80%) 843 (78%) 142 (79%)
ACE inhibitor/ARB 183 (47%) 570 (46%) 451 (42%) 91 (51%)
Aldosterone receptor antagonist 19 (5%) 65 (5%) 61 (6%) 10 (6%)
Sacubitril/valsartan 15 (4%) 42 (3%) 35 (3%) 6 (3%)
1

Of those surviving to discharge.

2

Of those surviving to 1 year.